PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.965
+0.295 (+3.85%)
As of 1:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.670
Open7.660
Bid7.950 x 800
Ask7.960 x 1100
Day's Range7.563 - 7.976
52 Week Range5.010 - 9.420
Volume718,016
Avg. Volume1,523,251
Market Cap667.865M
Beta2.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist6 days ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist7 days ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Opko Health: Q2 Expenditures, Developments, Recommendations
    Market Realist12 days ago

    Opko Health: Q2 Expenditures, Developments, Recommendations

    In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.

  • How Opko Health Fared in the Second Quarter of 2018
    Market Realist12 days ago

    How Opko Health Fared in the Second Quarter of 2018

    In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.

  • Benzinga20 days ago

    Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...

  • Associated Press21 days ago

    Progenics: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 20 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. Progenics shares have risen 34 percent since ...

  • FDA approves first non-surgical treatment for 2 rare cancers
    American City Business Journals21 days ago

    FDA approves first non-surgical treatment for 2 rare cancers

    The FDA's approval of Azedra followed clinical trails of the rare cancer therapy conducted at the University of Pennsylvania's Abramson Cancer Center in Philadelphia.

  • Benzinga21 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Apple Inc. (NASDAQ: AAPL ) is scheduled to release ...

  • 3 Big Stock Charts for Tuesday: Netflix, Unum Group and Dentsply Sirona
    InvestorPlace21 days ago

    3 Big Stock Charts for Tuesday: Netflix, Unum Group and Dentsply Sirona

    Stalwarts like Twitter (NYSE:TWTR) and Facebook (NASDAQ:FB), both of which set the pace for the rest of the market, continued last week’s tumbles. Progenics Pharmaceuticals (NASDAQ:PGNX) hammered out an 8% gain following news that one of its drugs won an approval from the FDA, and Advanced Micro Devices (NASDAQ:AMD) advanced more than 2% on Monday, still fueled by last week’s impressive earnings beat. With that as the backdrop, the stock charts of Netflix (NASDAQ:NFLX), Unum Group (NYSE:UNM) and Dentsply Sirona (NASDAQ:XRAY) say they’re the best-grounded trading setups … at least as it stands right now.

  • Reuters22 days ago

    FDA approves Progenics' treatment for rare adrenal gland tumors

    The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use. The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors - pheochromocytoma or paraganglioma - and require anti-cancer therapy, the FDA said https://bit.ly/2Ovz75p. The two tumor types affect the adrenal gland that releases the adrenaline hormone, which triggers the body's defense mechanism.

  • Reuters22 days ago

    FDA approves Progenics' treatment for two rare tumors

    The U.S. Food and Drug Administration on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of tumors. The drug, Azedra, was approved to treat some patients above the age of 12 who ...

  • Benzinga22 days ago

    The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO

    Below is a list of notable corporate events for the week beginning July 30. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMZN Monday ...

  • 3 Stocks That Could Double Your Money
    Motley Fool26 days ago

    3 Stocks That Could Double Your Money

    Find out why these three biotech stocks could be huge winners.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool2 months ago

    3 Biotech Stocks With Major Catalysts Incoming

    The third quarter of 2018 will be awfully exciting for owners of these three stocks.

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    InvestorPlace2 months ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. Key FDA approvals in the first half included Amgen (NASDAQ:AMGN)/Novartis’s first CGRP antibody Aimovig/erenumab for prevention of migraine, Johnson & Johnson’s (NYSE:JNJ) next-generation oral androgen receptor (“AR”) inhibitor Erleada (apalutamide) for pre-metastatic prostate cancer (CRPC), Vertex Pharmaceuticals’ (NASDAQ:VRTX) third medicine to treat the underlying cause of CF, Symdeko, which is a combination of tezacaftor and ivacaftor and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU). FDA Decision on Indivior’s Schizophrenia Injection RBP-7000: On Jul 28, the FDA is expected to give its decision on Indivior‘s (OTCMKTS:INVVY) RBP-7000, which has been developed for the treatment of schizophrenia.

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    Zacks2 months ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    In the first six months of the year, the FDA grants approval to 17 new treatments.

  • 3 Biotech Stocks With Major Potential Catalysts in July
    Motley Fool2 months ago

    3 Biotech Stocks With Major Potential Catalysts in July

    FDA approvals next month could be huge for these biotech stocks.

  • Is There An Opportunity With Progenics Pharmaceuticals Inc’s (NASDAQ:PGNX) 21% Undervaluation?
    Simply Wall St.2 months ago

    Is There An Opportunity With Progenics Pharmaceuticals Inc’s (NASDAQ:PGNX) 21% Undervaluation?

    In this article I am going to calculate the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) using the discounted cash flows (DCF) model. If you want to learn more aboutRead More...

  • Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth
    Zacks3 months ago

    Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth

    Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth

  • 5 Stocks in Focus on New Analyst Coverage
    Zacks3 months ago

    5 Stocks in Focus on New Analyst Coverage

    More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PGNX earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Progenics Pharmaceuticals Inc Earnings Call

  • Associated Press3 months ago

    Progenics: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 19 cents per share. The biopharmaceutical company posted revenue of $3.2 million in the period. Progenics shares have climbed 16 percent since the beginning ...

  • Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox
    Zacks3 months ago

    Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox

    Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox

  • New Analyst Coverage Puts Spotlight on These 4 Stocks
    Zacks3 months ago

    New Analyst Coverage Puts Spotlight on These 4 Stocks

    More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

  • Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven
    Simply Wall St.5 months ago

    Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven

    Progenics Pharmaceuticals Inc’s (NASDAQ:PGNX): Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. On 31 December 2017, the US$607.45M market-capRead More...